Windward Bio Prices IPO At $17.00 — Sanofi Investment Takes Expected Proceeds To $225 Million

The drug developer estimates it could need up to $227.5 million for studies of its lead antibody and another late-stage asthma trial.

Share
Windward Bio Prices IPO At $17.00 — Sanofi Investment Takes Expected Proceeds To $225 Million

Windward Bio, which develops long-acting antibody medicines for lung and skin diseases, priced its IPO at $17.00 a share Thursday. Its pricing announcement put expected gross proceeds from the offering and a separate Sanofi investment at $225 million, before fees and expenses.

Sanofi Adds $50 Million

Windward is selling all 10,294,117 IPO shares and is set to receive $175 million from the offering. The final price falls within the marketed $16.00–$18.00 range.

Sanofi Foreign Participations, the buyer in the separate placement, agreed to invest $50 million. It will buy 1,532,691 shares plus prefunded warrants—rights to buy shares with most of the purchase price paid upfront—covering 1,408,485 shares.

The underwriters have a 30-day option to buy up to 1,544,117 additional shares. Those shares are separate from the base offering and excluded from the $225 million proceeds estimate. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank jointly lead the share sales.

Asthma Results Stretch Into 2029

Windward estimated it could need up to $227.5 million to finish studies of its lead candidate, WIN378, and start another late-stage asthma trial.

WIN378 is designed for twice-yearly dosing. According to Windward's IPO registration statement, its asthma study entered the late-stage portion in September 2026; the company expects initial results in the first half of 2029. The antibody targets a protein involved in inflammation and is also being studied in chronic obstructive pulmonary disease.

Its other candidate, WIN027, targets two inflammation-related proteins and is being tested in healthy volunteers. Windward's broader focus includes atopic dermatitis, a form of eczema. Its licensed global rights exclude Greater China and certain Asian markets for WIN378, and Greater China for WIN027.

Windward licensed WIN378 from Kelun and Harbour BioMed and WIN027 from Qyuns, all Chinese biotechnology companies. It flagged reliance on those companies as a risk, including manufacturing that is being transferred to U.S. contract manufacturers.

Losses Before The Nasdaq Debut

Windward reported a $42.6 million loss for the six months ended June 30, 2026, versus $22.8 million a year earlier, with no product revenue. Cash, cash equivalents and marketable securities totaled $207.3 million at June 30.

Private investors provided $200 million in financing in 2025 and another $165 million earlier this year. Sanofi's venture arm participated in the latter financing.

Windward was incorporated in July 2024 and began operations in January 2025 under founder and CEO Luca Santarelli, who previously co-founded VectivBio and Therachon. Its registered office is in Basel, Switzerland, and its principal U.S. executive offices are in Dover, Delaware.

The recent biopharma IPO market offers a restrained backdrop: only two of seven companies that listed in October traded above their offering prices in coverage published Tuesday.

WWB shares are expected to begin trading Friday on the Nasdaq Global Select Market. Windward expects the IPO to close Monday, when the separate Sanofi placement is also scheduled to close.

Sources